Intravitreal Injection

Intravitreal Injection

Intravitreal injection is a service provided for patients suffering from retinal diseases such as diabetic retinopathy [link to Diabetic Retinopathy page] and wet age-related macular degeneration (AMD) [link to AMD page]. These conditions often involve the formation of new blood vessels, prompted to grow by a protein called Vascular Endothelial Growth Factor (VEGF). Injection of anti-VEGF drugs directly into the white part of the posterior cavity of the eye aims to halt the damages on the retina stemming from the formation of new retinal blood vessels.

Injection Suite

Every year, more than 2,500 anti-VEGF injection procedures were performed at our Injection Suites. Treatment using anti-VEGF drugs is administered as a long term treatment to control recurrent retinal conditions, especially wet AMD. The treatment is a day procedure without the need for hospitalization, and is done on a monthly basis.

The Anti-VEGF agents offered at our Injection Suites are:

  1. Lucentis/Accentrix (Ranibizumab)
  2. Avastin (Bevacizumab)
  3. Eylea (Aflibercept)

Anti-VEGF injection can also be combined with cold laser therapy to maximize its effectiveness. While treatment can stabilise vision, the choice of drugs and the degree of improvement depend on the timing of the diagnosis, the severity of retinal damage, subtype of AMD, as well as patient’s individual response to initial treatment.

Consultation with medical retina specialist is paramount in getting the best treatment outcome. Talk to our Consultant Ophthalmologists for your treatment today.

Find a doctor - Book an appointment


Senior Consultant Ophthalmologist


Senior Consultant Ophthalmologist


Senior Consultant Ophthalmologist